These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 15291979)

  • 21. The proteasome and proteasome inhibitors in cancer therapy.
    Voorhees PM; Orlowski RZ
    Annu Rev Pharmacol Toxicol; 2006; 46():189-213. PubMed ID: 16402903
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Heat shock protein 90 inhibitor BIIB021 (CNF2024) depletes NF-kappaB and sensitizes Hodgkin's lymphoma cells for natural killer cell-mediated cytotoxicity.
    Böll B; Eltaib F; Reiners KS; von Tresckow B; Tawadros S; Simhadri VR; Burrows FJ; Lundgren K; Hansen HP; Engert A; von Strandmann EP
    Clin Cancer Res; 2009 Aug; 15(16):5108-16. PubMed ID: 19671844
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Shifts in the therapeutic paradigm for patients newly diagnosed with multiple myeloma: maintenance therapy and overall survival.
    Palumbo A; Attal M; Roussel M
    Clin Cancer Res; 2011 Mar; 17(6):1253-63. PubMed ID: 21411441
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hematologic malignancies: new developments and future treatments.
    Cheson BD
    Semin Oncol; 2002 Aug; 29(4 Suppl 13):33-45. PubMed ID: 12170431
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interruption of tumor cell cycle progression through proteasome inhibition: implications for cancer therapy.
    Dou QP; Smith DM; Daniel KG; Kazi A
    Prog Cell Cycle Res; 2003; 5():441-6. PubMed ID: 14593738
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical development of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors: what lessons have we learned?
    Hidalgo M
    Adv Exp Med Biol; 2008; 610():128-43. PubMed ID: 18593020
    [No Abstract]   [Full Text] [Related]  

  • 27. Chemoimmunotherapy versus chemotherapy for remission induction in patients with non-Hodgkin's lymphoma: progress report of a Southwest Oncology Group study.
    Jones SE
    Recent Results Cancer Res; 1978; 65():164-9. PubMed ID: 85322
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Increased in vivo efficacy of lenalidomide and thalidomide by addition of ethacrynic acid.
    Schmidt M; Kim Y; Gast SM; Endo T; Lu D; Carson D; Schmidt-Wolf IG
    In Vivo; 2011; 25(3):325-33. PubMed ID: 21576405
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Servier oncology pipeline in 2017.
    Therasse P; Perron B; Novack SA; Abastado JP
    Future Oncol; 2017 Jul; 13(17):1527-1536. PubMed ID: 28427281
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diffuse aggressive lymphoma.
    Fisher RI; Miller TP; O'Connor OA
    Hematology Am Soc Hematol Educ Program; 2004; ():221-36. PubMed ID: 15561685
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tumor necrosis factor ligand-receptor system can predict treatment outcome in lymphoma patients.
    Warzocha K; Salles G; Bienvenu J; Bastion Y; Dumontet C; Renard N; Neidhardt-Berard EM; Coiffier B
    J Clin Oncol; 1997 Feb; 15(2):499-508. PubMed ID: 9053471
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel therapies targeting the myeloma cell and its bone marrow microenvironment.
    Hideshima T; Chauhan D; Podar K; Schlossman RL; Richardson P; Anderson KC
    Semin Oncol; 2001 Dec; 28(6):607-12. PubMed ID: 11740818
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combined inhibition of Hsp90 and the proteasome affects NSCLC proteostasis and attenuates cell migration.
    Zismanov V; Drucker L; Gottfried M
    Anticancer Drugs; 2014 Oct; 25(9):998-1006. PubMed ID: 25153785
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lenalidomide: a novel anticancer drug with multiple modalities.
    Galustian C; Dalgleish A
    Expert Opin Pharmacother; 2009 Jan; 10(1):125-33. PubMed ID: 19236186
    [TBL] [Abstract][Full Text] [Related]  

  • 35. DNA repair pathways as targets for cancer therapy.
    Helleday T; Petermann E; Lundin C; Hodgson B; Sharma RA
    Nat Rev Cancer; 2008 Mar; 8(3):193-204. PubMed ID: 18256616
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Marked clinical activity of the proteasome inhibitor bortezomib in patients with follicular and mantle-cell lymphoma.
    O'Connor OA
    Clin Lymphoma Myeloma; 2005 Nov; 6(3):191-9. PubMed ID: 16354324
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of refractory and relapsed Hodgkin's lymphoma: facts and perspectives.
    Brusamolino E; Carella AM
    Haematologica; 2007 Jan; 92(1):6-10. PubMed ID: 17229629
    [No Abstract]   [Full Text] [Related]  

  • 38. New drugs in non-Hodgkin's lymphoma.
    Arbuck SG; Sorensen JM; Christian MC; Ho P; Pluda JM; Cheson BD
    Ann Oncol; 1997; 8 Suppl 1():119-28. PubMed ID: 9187445
    [TBL] [Abstract][Full Text] [Related]  

  • 39. What is the role of autologous transplant for lymphoma in the current era?
    Stiff P
    Hematology Am Soc Hematol Educ Program; 2015; 2015():74-81. PubMed ID: 26637704
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pediatric Oncology Group experience with modified LSA2-L2 therapy in 107 children with non-Hodgkin's lymphoma (Burkitt's lymphoma excluded).
    Sullivan MP; Boyett J; Pullen J; Crist W; Doering EJ; Trueworthy R; Hvizdala E; Ruymann F; Steuber CP
    Cancer; 1985 Jan; 55(2):323-36. PubMed ID: 3880656
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.